AZD4877, with the CAS number 1176760-49-8, is a chemical compound that has been investigated primarily for its potential therapeutic applications, particularly in the context of cancer treatment. It is classified as a selective androgen receptor modulator (SARM), which means it is designed to selectively target androgen receptors in specific tissues, potentially offering benefits similar to anabolic steroids without the associated side effects. AZD4877 exhibits a unique chemical structure that allows it to bind to androgen receptors with a degree of specificity, promoting anabolic activity in muscle and bone while minimizing effects on other tissues. Its pharmacological profile suggests it may enhance muscle mass and strength, making it of interest in both medical and athletic contexts. However, as with many investigational compounds, its safety, efficacy, and long-term effects are subjects of ongoing research. Understanding its characteristics, including solubility, stability, and metabolic pathways, is crucial for evaluating its potential applications in clinical settings.

AZD4877

1176760-49-8: AZD4877, with the CAS number 1176760-49-8, is a chemical compound that has been investigated primarily for its potential therapeutic applications, particularly in the context of cancer treatment. It is classified as a selective androgen receptor modulator (SARM), which means it is designed to selectively target androgen receptors in specific tissues, potentially offering benefits similar to anabolic steroids without the associated side effects. AZD4877 exhibits a unique chemical structure that allows it to bind to androgen receptors with a degree of specificity, promoting anabolic activity in muscle and bone while minimizing effects on other tissues. Its pharmacological profile suggests it may enhance muscle mass and strength, making it of interest in both medical and athletic contexts. However, as with many investigational compounds, its safety, efficacy, and long-term effects are subjects of ongoing research. Understanding its characteristics, including solubility, stability, and metabolic pathways, is crucial for evaluating its potential applications in clinical settings.

AZD 4877 is a novel new drug that inhibits the tumor-promoting growth factor TGF-β. It has been shown to inhibit the proliferation of bladder and kidney cancer cells, as well as T-cell lymphomas. AZD 4877 also inhibits the production of proinflammatory cytokines and induces apoptotic cell death in vitro. In addition, this drug downregulates the expression of SIRT2 and p21/WAF1 pathways, which are responsible for cell growth and survival. Clinical studies have shown that AZD 4877 has an inhibitory effect on urothelial carcinoma cells in vivo.

CAS 1176760-49-8

AZD4877

AZD 4877

Ref: 3D-FA172879